Idiopathic Short Stature is categorized into Familial Short Stature (FSS) - when the child remains in the range of target height but have short stature compared to reference population and Non-Familial Short Stature (NFSS) - a child is short statured when compared with both reference population and the target height.
Factors driving global demand for Idiopathic Short Stature are increasing awareness amongst people and increasing number of growth hormone options available in the market.
This report provides information on Idiopathic Short Stature market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to Idiopathic Short Stature treatment market.
United States and Europe remain the potential markets for Idiopathic Short Stature accounting for more than four million children. Availability of insurance aid in developed markets increases the penetration of the biologics/biosimilar drugs used in the treatment of Idiopathic Short Stature. The market is dominated by few major players, which indeed has become a major challenge for the new entrants.
This report identifies global Idiopathic Short Stature market on the basis of treatment type and regional market as follows:
Idiopathic Short Stature treatment market is segmented based on available treatment options. Although various treatment options are in the market majority of these are not approved for growth acceleration and hence they are considered under off label use. Recombinant growth hormone therapy, Insulin like Growth Factor -1 (IGF-1) therapy, Aromatase inhibitors and low-dose androgen therapy (with injectable testosterone and low dose androgen) are the available treatment options.
This report is further segmented based on potential markets for Idiopathic Short Stature. A detailed analysis by region – North America, Europe, Asia Pacific (APAC) and Rest of the World (RoW), has been provided in this report.
This report looks into all the major companies operating in the Idiopathic Short Stature treatment. Some of the major companies’ profiles are as follows:
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Idiopathic Short Stature Market - Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Idiopathic Short Stature Market - Market Forces
4.1.1. Increasing awareness amongst people
4.1.2. Increasing number of growth hormone options
4.2.1. High cost for developing the drugs
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Customers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Idiopathic Short Stature Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Idiopathic Short Stature Market, By Treatment Type
6.1. Growth Hormone Replacement Therapy
6.2. Insulin like Growth Factor -1 (IGF-1) Therapy
6.3. Aromatase inhibitors and low-dose androgen therapy
7. Idiopathic Short Stature Market, By Geography
7.2. North America
7.3.6. Rest of Europe
7.4. Asia Pacific
7.4.2. South Korea
7.4.5. Rest of Asia Pacific
8. Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply - Contract
9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. Eli Lilly
9.3. Novo Nordisk
9.4. Merck KGaA
9.7. JCR Pharmaceuticals
9.8. Ferring Pharmaceuticals
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.4. Expert Insights